A clinical trial of the effects and safety of ra76 cream on remission maintenance of atopic dermatitis.

Not Applicable

• Conditions: Atopic dermatitis

• Registration Number: JPRN-UMIN000025722
• Lead Sponsor: Exam CO.,LTD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-01-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 18

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with severe skin disorders on test site (both arms) and deemed inappropriate to participate in this study by the principal investigator or sub-investigators. 2) Patients with any complications which affect the results of this study. 3) Patients who might use any external use medicines, anti-allergy drugs, or immunosuppressants. 4) Patients with a past history of allergy with test drug components. 5) Patients with hemorrhagic disease. 6) Patients with risk of serious disease in an injury. 7) Patients with menopausal trouble or on menopausal hormone therapy 8) Pregnant or lactating patients. Patients with suspicion of pregnancy. 9) Patients deemed inappropriate to participate in this study by the principal investigator or sub-investigators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The period of the remission maintenance of atopic dermatitis in ra76 cream or active comparator applying term.

Secondary Outcome Measures

Name	Time	Method
1) Severity classification (simple method) of atopic dermatitis developed by the advisory committee of atopic dermatitis severity classification of Japanese Dermatological Association at test site (both arms). 2) Transepidermal water loss, water content of the stratum corneum, erythema and pigmentation, and skin surface topography at test site (both arms), etc. 3) Questionnaires for QOL assessment in atopic dermatitis.